Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 7/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22864038 | 0.95 | IDO1 (0.44) | IDO1ABL1METAP2ADRB2ADRB1 | |
| SCHEMBL24631019 | 0.85 | IDO1 (0.58) | IDO1METAP2ADRB2ADRB1PRMT5 | |
| SCHEMBL24631027 | 0.81 | ADRB2 (0.46) | IDO1METAP2ADRB2ADRB1 | |
| SCHEMBL24630923 | 0.80 | IDO1 (0.56) | IDO1METAP2ADRB2ADRB1 | |
| SCHEMBL22864095 | 0.80 | IDO1 (0.43) | IDO1METAP2 | |
| SCHEMBL24630903 | 0.80 | IDO1 (0.43) | IDO1METAP2ADRB2ADRB1 | |
| SCHEMBL22864083 | 0.79 | IDO1 (0.41) | IDO1ABL1METAP2 | |
| SCHEMBL24631034 | 0.79 | IDO1 (0.59) | IDO1ADRB2ADRB1PRMT5 | |
| SCHEMBL22864081 | 0.77 | IDO1 (0.40) | IDO1ABL1METAP2 | |
| SCHEMBL22864291 | 0.76 | ADRB2 (0.40) | IDO1ADRB2ADRB1PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220315534-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. | 2022-10-06 | — | — | US | disclosed |
| WO-2021003161-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315534-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | ADRB2, ADRB1, ADRA2C | IDO1 3184/4885ABL1 2814/4885METAP2 922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.